January 27-29, 2026 | Boston, MA

Register & Pay by Friday, October 17 to Save $900



9th Annual

# DDR Inhibitors Summit

Driving Mechanistic Advances in Next-Generation DDR Inhibitors

## Validate Novel Targets & Utilize Biomarker-Driven Combination Strategies to Accelerate the Development of Durable, Selective & Low-Toxicity DDR Therapeutics

**Alan D'Andrea**
Director of the Center for DNA Damage and Repair
**Dana-Farber Cancer Institute**

**Ioannis Gounaris**
Vice President - Clinical Development
**Merck**

**Jatinder (Jyoti) Mukker**
Senior Director, Quantitative Pharmacology Portfolio Section Head
**EMD Serono**

**Sotirios Sotiriou**
Principal Scientist - pRED Oncology
**Roche**

**Graeme Smith**
Chief Scientific Officer
**Artios Pharma**

**Timothy Yap**
Vice President & Head of Clinical Development & Therapeutics Discovery Medical, Institute for Applied Cancer Science
**MD Anderson Cancer Center**

**"The presentations and speakers were great, as was the networking. This is one of the top DDR-focused conferences, and really important to keep the field moving forward."**

**Charles Sinclair**, Vice President & Head of Translational Sciences, **Flagship Pioneering**

# Uniting Industry Leaders to Fast-Track Discovery & Development of Durable, Selective & Low-Toxicity DDR-Targeted Therapies

"The DDR field is approaching a critical point of validation, going beyond the first-generation PARP drugs, with many new agents in early development. Year on year, this conference brings together key leaders and decision-makers striving to advance this field to the benefit of underserved patients."

**Jon Hollick**, Managing Director & Head of Research, **Breakpoint Therapeutics**

"This meeting provides practical knowledge of the opportunities and challenges in moving therapeutic concepts from basic research to clinical trials and patient benefit."

**Eric Brown**, Associate Professor & Scientific Consultant, **University of Pennsylvania**

As more than a decade has passed since the PARP inhibitor Olaparib became the first DNA Damage Response (DDR)-targeted therapy to win regulatory approval, the field is at a pivotal inflection point. Despite over 500 candidates in clinical trials, no other DDR inhibitor class beyond PARP has reached the market. While innovation is accelerating, translating synthetic lethality and mechanistic insights into approved therapies remains a major challenge.

Today, drug developers are expanding the DDR target space beyond PARP to include ATR, CHK1/2, DNA-PK, WEE1, WRN, Polθ, and other novel mechanisms. At the same time, functional genomics, predictive biomarkers, and replication stress assays are being refined to improve patient selection, guide dosing, and unlock smarter combinations with radiotherapy, chemotherapy, ADCs, and radiopharmaceuticals.

Now in its 9th year, the DDR Inhibitors Summit is the definitive meeting for translational scientists, clinical developers, and biotech innovators advancing DDR-targeted oncology. With a sharp focus on synthetic lethality, biomarker-driven patient selection, and next-generation DDR mechanisms, this year's summit delivers actionable insights and strategic collaboration to overcome resistance, improve durability, and fast-track clinical success

Across three content-rich days, you'll gain practical solutions and strategic direction on how to:

- **Expand the DDR target space** beyond PARP by validating novel targets and emerging mechanisms such as replication stress, WRN, and Polθ
- **Enhance therapeutic efficacy** through smarter DDR combinations with radiotherapy, chemotherapy, ADCs, and radiopharmaceuticals
- **Accelerate clinical success** by leveraging functional and predictive biomarkers, optimized dosing strategies, and validated diagnostics
- **Overcome resistance mechanisms** through next-generation modalities, dual-payload ADCs, and innovative trial designs
- **Foster strategic academic–industry partnerships** & unlock investor insights to accelerate DDR innovation and venture creation

With new content on biomarkers, translational science, and biotech innovation, this year's meeting provides the insights and partnerships you need to fast-track safer, more effective therapies to patients.

## What's New for 2026:

### Breakthrough Biomarker Strategies for Patient Selection & Dosing

Hear from the **University of Pennsylvania**, **Step Pharma**, and **Merck** on the latest advances in functional and predictive biomarkers, including replication stress markers and single-cell proteomics, to improve patient stratification and guide combination strategies

### Expanding the DDR Target Space Beyond PARP

Sessions led by **University of Oxford**, **Accent Therapeutics**, **Beat Therapeutics**, **MD Anderson Center**, and more will showcase the new data emerging on DDR targets such as ATR, CHK1/2, DNA-PK, WEE1, Polθ, and DHX9, with a focus on first-in-class molecules and differentiated mechanisms

### Smarter Combination Approaches

**Artios Pharma**, **VSPharmTech** & **The University of Glasgow** will present translational and clinical updates on combining DDR inhibitors with radiotherapy, chemotherapy, ADCs, and radiopharmaceuticals to overcome resistance and improve durability of response

### Biotech Innovation & Academic-Industry Collaboration

Join discussions featuring academic founders, biotech entrepreneurs, and investors from **Rakovina Therapeutics**, **Modifi Bio** & **Breakpoint Therapeutics**, sharing lessons on translating DDR discoveries into new ventures and building strategic partnerships

# Your 30 Expert Speakers

## Industry Speakers:

**Angela Carvalho**
Co-Founder & Chief Executive Officer
**Beat Therapeutics**

**Philip Beer**
Chief Scientific Officer
**Step Pharma**

**Jack Cheng**
Associate Director - Preclinical Research
**PharmaEngine, Inc**

**Jennifer Castro**
Director of Translational & Discovery Biology
**Accent Therapeutics**

**Ioannis Gounaris**
Vice President - Clinical Development
**Merck**

**Irena Konstantinova**
Head of Biology
**FoRx Therapeutics**

**Jatinder (Jyoti) Mukker**
Senior Director & Portfolio Section Head, Quantitative Pharmacology
**EMD Serono**

**Jon Hollick**
Managing Director & Head of Research
**Breakpoint Therapeutics**

**Hyun-Ho Lee**
Chief Technology Officer & Head of R&D
**VSPharmTech**

**Katherine Pawelczak**
Chief Operating Officer
**Nerx BioSciences Inc.**

**Graeme Smith**
Chief Scientific Officer
**Artios Pharma**

**Ian Smith**
Chief Medical Officer
**Artios Pharma**

**Luke Piggott**
Principal Scientist & Director Business Development
**Debiopharm**

**Michail Shipitsin**
Vice President Biomarker Development
**Acrivon Therapeutics**

**Michael Torres**
Chief Executive Officer
**CrossBridge Bio**

**Sotirios Sotiriou**
Principal Scientist - pRED Oncology
**Roche**

**Wei Zhong**
Chief Executive Officer
**Wayshine Pharma**

**Yuka Kumagai**
Senior Vice President & Head of Translational Research & Medicine
**Sumitomo Pharma America**

**Zakia Belaid-Sandal**
Chief Executive Officer & Co-Founder
**Theranovir**

# Your 30+ Expert Speakers

## Academic Entrepreneurs:

**Mads Daugaard**
Co-founder, President, Chief Scientific Officer & Associate Professor
**Rakovina Therapeutics & University of British Columbia**

**Ranjit Bindra**
Co-Founder & Professor, Co-Director, Brain Tumor Center
**Modifi Bio (Acquired by Merck & Co) & Yale Univerisity**

## Academic Speakers:

**Alan D'Andrea**
Director of the Center for DNA Damage and Repair
**Dana-Farber Cancer Institute**

**Anthony Chalmers**
Professor & Clinical Oncology Chair
**University of Glasgow**

**David Mankoff**
Professor Radiology
**University of Pennsylvania**

**Eric J. Brown**
Associate Professor & Scientific Consultant
**University of Pennsylvania**

**Jann Sarkaria**
Professor of Radiation Oncology Medical & Health
**Mayo Clinic**

**Ivan Ahel**
Professor of Chemical Pathology
**University of Oxford**

**Samuel Rabkin**
Professor of Neurosciences
**Harvard Medical School**

**Shridar Ganesan MD**
Director, Center for Molecular Oncology
**Perlmutter Cancer Center NYU Langone Health**

**Timothy Yap**
Vice President & Head of Clinical Development & Therapeutics Discovery Medical, Institute for Applied Cancer Science
**MD Anderson Cancer Center**

**"Addressing resistance and durability requires new mechanisms and smart combination strategies.**

**This conference offers a chance to learn about one of the most exciting classes of therapies shaping the future of oncology."**

**Michael Torres**, Chief Executive Officer, **CrossBridge Bio**

# Pre-Conference Biomarker Focus Day

## Precision Tools for Smarter DDR Development

Tuesday, January 27, 2026

DDR Inhibitors Summit
January 27-29, 2026
Boston, MA

8.30 **Check-In, Coffee & Networking**

9:20 **Chair's Opening Remarks**

## Aligning Translational Biomarker Strategy to Guide Smarter Dosing, Strengthen Trial Design & Drive Patient-Centric DDR Development

9:30 **Panel: Unlocking the Full Potential of Biomarkers to Transform DDR Drug Development**

- Exploring the evolving role of biomarkers in DDR therapy, from predictive tools to dynamic response monitors
- Evaluate the challenges of biomarker complexity, standardization, and clinical implementation
- Sharing cross-sector insights on integrating biomarkers into trial design, dosing strategies, and regulatory pathways

**Luke Piggott**
Principal Scientist & Director Business Development
**Debiopharm**

**Michail Shipitsin**
Vice President Biomarker Development
**Acrivon Therapeutics**

10:00 **Applying Model Informed Drug Development to Select & Optimize Clinical Dosage in DDR Combination Therapies**

- Evaluating Project Optimus implications for DDR programs and how proactive pharmacological modeling accelerates clinical success
- Highlighting the challenges of dose selection in DDR inhibitor combinations, balancing efficacy with tolerability
- Showcasing how model-based drug development leverages preclinical and clinical data to guide smarter escalation and expansion strategies

**Jatinder (Jyoti) Mukker**
Senior Director & Portfolio Section Head, Quantitative Pharmacology
**EMD Serono**

10.30 **Morning Break & Networking**

## Advancing Predictive Biomarker Strategies to Expand Patient Access & Enable DDR Combinations

11:00 New Data **Moving from Single Gene to Combination Biomarkers to Improve Predictive Power of Treatment Response**

- Diagnosing why single-gene mutation biomarker approaches often underperform, highlighting the need for additional predictors of response
- Presenting combination biomarker concepts, e.g., CCNE-amp + co-alterations and pathway-level logic
- Exploring adaptive enrichment designs for DDR therapies with consideration of prevalence and implementation feasibility

**Eric J. Brown**
Associate Professor & Scientific Consultant
**University of Pennsylvania**

11:30 New Data **Leveraging Replication Stress Biomarkers to Guide DDR Combination Strategies**

- See how Step Pharma are leveraging data-driven discovery of replication stress as a predictive biomarker, linking novel agents with ATR and WEE1 synergy
- Sharing preclinical insights while outlining the translational challenges of moving from complex preclinical signatures to clinical assays
- Balancing biomarker complexity with clinical feasibility to inform future DDR combination strategies

**Philip Beer**
Chief Scientific Officer
**Step Pharma**
New Company

12:00 **Networking Lunch**

# Pre-Conference Biomarker Focus Day

## Precision Tools for Smarter DDR Development

Tuesday, January 27, 2026

DDR Inhibitors Summit
January 27-29, 2026
Boston, MA



## Applying Translational Biomarker Insights to Enhance Therapy Efficacy & Accelerate Clinical Success

1:15 **Enhanced Tumor Targeting & Therapeutic Window Expansion with SMP-3124: A Novel Liposome-Encapsulated CHK1 Inhibitor**

- See how Sumitomo Pharma America are enhancing tumor targeting with their novel liposomal CHK1 inhibitor, SMP-3124.
- Highlighting translational research insights that improve the likelihood of tumor response while mitigating toxicity limitations seen with earlier CHK1 programs
- Providing a trials-in-progress update on the ongoing Phase I study, sharing design, patient cohorts, and a general summary

**Yuka Kumagai**
Senior Vice President, Head of Translational Research & Medicine
**Sumitomo Pharma America**

1:45 **Harnessing ATR Inhibition in ATRX-Mutant Gliomas to Deliver Durable Responses in Poor-Prognosis Patients**

- See how Merck are demonstrating durable responses with ATR inhibition in ATRX-mutant gliomas, a poor-prognosis subtype.
- Outlining the synthetic lethality rationale linking ATRX loss, alternative lengthening of telomeres (ALT), and ATR dependency
- Presenting ongoing studies confirming early signals and discuss opportunities to integrate biomarker-driven patient selection into glioma trial design

**Ioannis Gounaris**
Vice President - Clinical Development
**Merck**

2:15 **Afternoon Break & Networking**

## Translating Biomarker Strategy to Optimize Dosing, Minimize Toxicity & Guide Combinations

2:45 **Roundtable Discussion: Harnessing Biomarker Insights to Optimize Dosing Precision, Sample Reliability & Combination Therapy Design**

### Balancing Efficacy and Safety Through Biomarker-Guided Dosing

- How can predictive and pharmacodynamic biomarkers be integrated to define the therapeutic window?
- What are the key challenges in translating preclinical biomarker data into dosing strategies in patients?

### Ensuring Sample Quality & Standardization to Strengthen Translational DDR Research

- What standardized approaches to sample collection and processing are essential to ensure reliable biomarker readouts?
- How can improved sample quality accelerate translation from patient samples to preclinical models and clinical trial design?

### Designing & Deploying Combination Biomarkers to Guide DDR Combination Therapies

- How can combination biomarkers be structured to both increase prediction accuracy while maintaining the rate of patient eligibility?
- What practical approaches make composite biomarker panels feasible in clinical trials while meeting regulatory expectations?

3:30 **Roundtable Feedback Panel**

- Following the separate roundtable discussions, this session is dedicated for the roundtable leaders to share insights, outcomes, and further questions raised on each table
- This will be a panel format, taking audience questions to close off the day

**Eric J. Brown**
Associate Professor & Scientific Consultant
**University of Pennsylvania**

**Philip Beer**
Chief Scientific Officer
**Step Pharma**

4:00 **Chair's Closing Remarks**

# Conference Day One

## Wednesday, January 28, 2026





**7:30** **Check-In, Coffee & Light Breakfast**

**8:20** **Chair's Opening Remarks**

## Evaluating Emerging DDR Targets to Overcome Translational Barriers & Drive Smarter Development Decisions

**8:30** **Panel: Examining Why Promising DDR Targets Fail to Strengthen Future Development Strategies**

- Highlighting the key reasons DDR programs stall, including weak mechanistic rationale, limited biomarker support, and poor patient stratification
- Presenting real-world case studies from biotech and academia on programs that failed to translate, and the lessons learned
- Exploring how early decisions around target selection, dosing, and trial design impact clinical success
- Identifying practical strategies to improve target validation, including functional assays, predictive biomarkers, and more robust preclinical models

**Ioannis Gounaris**
Vice President - Clinical Development
**Merck**

**Jann Sarkaria**
Professor of Radiation Oncology Medical & Health
**Mayo Clinic**

**Sotirios Sotiriou**
Principal Scientist - pRED Oncology
**Roche**

**Alan D'Andrea**
Director of the Center for DNA Damage and Repair
**Dana-Farber Cancer Institute**

**Jatinder (Jyoti) Mukker**
Senior Director & Portfolio Section Head, Quantitative Pharmacology
**EMD Serono**

**9.15** **Exploring "Hot" PARP Inhibitors to Overcome Resistance and Improve Patient Response**

- Uncovering the rationale for "hot" PARP inhibitors to address resistance seen with conventional agents
- Examining resistance mechanisms and the role of biomarkers like PET imaging in guiding treatment
- Outlining combination strategies to boost efficacy while managing toxicity challenges

**David Mankoff**
Professor Radiology
**University of Pennsylvania**

**9:45** **Expanding Beyond PARP to Unlock Novel Hydrolase Pathways for DDR Drug Discovery**

- Illustrating the complexity of PARP-dependent pathways and highlight underexplored hydrolases, regulators, and effectors with therapeutic potential
- Showcasing emerging early-stage discovery programs targeting alternative hydrolases as biomarkers and drug targets
- Encouraging broader exploration of DDR biology to avoid "PARP tunnel vision" and inspire innovation in next-generation DDR therapies

**Ivan Ahel**
Professor of Chemical Pathology
**University of Oxford**

**10:15** **Speed Networking**
A prime opportunity to engage in-person with fellow experts and forge valuable connections as new companies enter and established players expand their presence within the DDR inhibitor space. Designed to maximize your interaction with thought leaders, share insights, and spark discussions at this uniquely focused summit tailored for scientists and drug development professionals

**10:45** **Morning Break & Networking**

## Targeting Foundational DDR Mechanisms to Improve Specificity, Overcome Resistance & Enable Durable Clinical Responses

**11.00** New Data **Targeting Polθ's Dual Domains to Guide Candidate Selection & Strategic Partnering**

- See how Breakpoint Therapeutics are guiding candidate selection by comparing helicase vs. polymerase inhibition to inform domain targeting
- Presenting Breakpoint's candidate molecule and second-generation compound with updated preclinical efficacy and safety data
- Contextualizing Breakpoint's program within the broader Polθ landscape to highlight differentiation and partnering potential

**Jon Hollick**
Managing Director & Head of Research
**Breakpoint Therapeutics**

# Conference Day One

## Wednesday, January 28, 2026





11.30

New Data

### Targeting Ku-DNA Binding to Improve Specificity, Reduce Toxicity & Advance Next-Generation DDR Therapeutics

- Introducing Ku as the first responder to DNA double-strand breaks and a novel DDR target distinct from kinase inhibitors
- See how Nerx BioSciences are disrupting Ku-DNA interactions to block DNA-PK activity with greater specificity and reduced toxicity
- Demonstrating how this upstream approach could deliver safer and more effective DDR therapies compared to traditional kinase inhibition

**Katherine Pawelczak**
Chief Operating Officer
**Nerx BioSciences Inc.**

12:00

New Data

### Expanding the DDR Target Landscape: Therapeutic Potential of BRCA1-Mediated Pathways

- See how Beat Therapeutics are targeting BRCA1-mediated pathways with a first-in-class small molecule
- Highlighting BRCA1-BARD1 disruption which impacts downstream repair pathways and present synergistic potential with standard-of-care therapies
- Investigating the therapeutic potential of BRCA1 inhibition to restore sensitivity in resistant cancers

**Angela Carvalho**
Co-Founder & Chief Executive Officer
**Beat Therapeutics**

New Company

12:30 **Networking Lunch**

## Advancing Next-Gen Modalities & Radiosensitization Strategies to Overcome Resistance & Achieve Durable Tumor Control

1:45

New Data

### Validating DNA-PK Inhibition as a Radiosensitizer to Overcome Past Challenges & Advance into the Clinic

- Reviewing lessons learned from past DNA-PK inhibitor programs and how improved potency, PK, and selectivity address prior limitations
- See how Wayshine Pharma are advancing WN-C001 to enhance radiotherapy efficacy with a favorable safety profile
- Highlighting translational insights and the development path toward clinical validation of DNA-PK inhibition as a radio-sensitization strategy

**Wei Zhong**
Chief Executive Officer
**Wayshine Pharma**

Combination Strategy

2:15

New Data

### Disrupting DDR Signaling by Targeting Leptin-Dependent NRP-1/OBR with NOV2 to Overcome Resistance & Induce Chromosomal Instability

- See how Theranovir are developed NOV2, a monoclonal antibody targeting the Leptin-dependent NRP-1/OBR complex involved in DDR signaling and nuclear translocation
- Sharing preclinical data demonstrating NOV2's ability to induce chromosomal instability, including centromere disruption and telomere shortening
- Exploring NOV2's potential to overcome resistance and relapse, and its future use in combination with PARP inhibitors

**Zakia Belaid-Sandal**
Chief Executive Officer & Co-Founder
**Theranovir**

New Company

2:45

New Data

### Harnessing Dual-Payload ADC Design to Enhance Efficacy, Minimize Toxicity, & Overcome Resistance

- See how CrossBridge Bio are designing dual-payload ADCs to address key clinical questions on efficacy, durability, and safety
- Presenting preclinical evidence which demonstrates how proprietary dual-payload ADCs act synergistically to delay or prevent resistance in tumor models, including activity in resistant settings
- Revealing non-human primate data highlighting an improved therapeutic index and lack of overlapping toxicities compared to single-payload ADCs

**Michael Torres**
Chief Executive Officer
**CrossBridge Bio**

New Company Combination Strategy

# Conference Day One

Wednesday, January 28, 2026





3:15 **Afternoon Break & Scientific Poster Session**

This is an informal session to connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of preclinical, translational, and clinical scientists eager to hear the latest advancements in DDRi therapeutic development, you will have the opportunity to display a poster presenting your own work and innovations.

## Investigating DDR Combination Strategies in Preclinical Models to Advance Mechanism-Driven Therapeutic Innovation

3:45 **Integrating Oncolytic Viruses with DDR Inhibitors to Drive Progress in Glioblastoma Therapy**

- Highlighting oncolytic herpes simplex virus (oHSV) combinations with DDR inhibitors that synergize in treating glioblastoma
- Using patient-derived human and mouse glioblastoma stem-like cells (GSCs) as representative preclinical models to assess therapy
- Targeting cancer stem cells with DNA-PK inhibitors and oHSV

**Samuel Rabkin**
Professor of Neurosciences
**Harvard Medical School**

Combination Strategy

4:15 **Combining Brain-Penetrant CHK1 & PRMT5 Inhibitors to Enhance Efficacy & Optimize Pharmacodynamics in Preclinical Models**

- See the rationale behind PharmaEngine's combination of CHK1 and PRMT5 inhibitors with preclinical examples
- Understanding alternation of pharmacodynamic markers of CHK1 and PRMT5 post corresponding inhibitor treatments
- Discovering combinations of CHK1 or PRMT5 inhibitors to standard of cares (SoCs) in corresponding indications

**Jack Cheng**
Associate Director - Preclinical Research
**PharmaEngine, Inc**

New Company | Combination Strategy

4:45 **Chair's Closing Remarks**

5:00 **End of Conference Day One**

**"The DDR Inhibitors Summit brings together professionals, thought leaders, and experts.**

**It's an excellent chance to share ideas, stimulate innovation to overcome challenges, and even forge partnerships or collaborations that could benefit future projects."**

**Wei Zhong**, Chief Executive Officer, **Wayshine Pharma**

# Conference Day Two

## Thursday, January 29, 2026





**8:00** **Check-In, Coffee & Light Breakfast**

**8:50** **Chair's Opening Remarks**

## Forging Industry-Academia-Investor Partnerships to Secure Funding & Accelerate DDR Pipeline Growth

**9:00** **Fireside Chat: Empowering Academic Entrepreneurs to Translate DDR Discoveries Into Impactful Biotech Ventures**

- Sharing real-world stories from scientists who launched successful DDR-focused startups
- Discussing practical steps for IP strategy, equity negotiations, and CEO recruitment
- Highlighting university-industry collaboration models that accelerate translation

**Mads Daugaard**
Co-founder, President, Chief Scientific Officer & Associate Professor, Department of Urologic Science
**Rakovina Therapeutics & University of British Columbia**

**Ranjit Bindra**
Co-Founder & Professor, Co-Director, Brain Tumor Center
**Modifi Bio (Acquired by Merck & Co) & Yale Univerisity**

**9.30** **Panel: Uniting Founders and Funders to Align Scientific Vision with Investment Strategy**

- Bringing together academic founders and investors to explore what makes DDR programs fundable
- Examining licensing, MTA bottlenecks, and funding models across early and late-stage ventures
- Offering insights into risk assessment, strategic partnerships, and scaling innovation

**Graeme Smith**
Chief Scientific Officer
**Artios Pharma**

**Mads Daugaard**
Co-founder, President & Chief Scientific Officer
**Rakovina Therapeutics**

**Jon Hollick**
Managing Director & Head of Research
**Breakpoint Therapeutics**

**10:00** **Morning Break & Networking**

## Advancing DDR–Radiotherapy & Chemotherapy Combinations to Overcome Resistance & Improve Clinical Outcomes

**10:30** **Modulating DDR in GBM to Enable Radiosensitizer-Driven Combination Strategies**

New Data

- See how VSPharmTech are developing VS-101 to enable radiosensitizer-driven strategies in glioblastoma
- Clarifying synthetic lethality and combination strategies in GBM
- Exploring regulatory and orphan drug designation progress

**Hyun-Ho Lee**
Chief Technology Officer and Head of R&D
**VSPharmTech**

New Company | Combination Strategy

**11:00** **Harnessing PARP & ATM Inhibitors With Radiotherapy to Improve Glioblastoma Outcomes While Safeguarding Cognitive Function**

- Presenting phase I data on radiotherapy with PARP inhibitors (olaparib, niraparib) across diverse GBM patient populations
- Detailing insights from first-in-human radiotherapy + ATM inhibitor studies advancing into randomized phase II/III trials
- Affirming preclinical evidence that PARP and ATM inhibitors both radio sensitize GBM tumors and protect healthy brain tissue from radiation-induced cognitive decline

**Anthony Chalmers**
Professor & Clinical Oncology Chair
**University of Glasgow**

Combination Strategy

# Conference Day Two

## Thursday, January 29, 2026





11:30 **Harnessing ATR Inhibition With Low-Dose Chemotherapy to Deliver Durable Responses in ATM-Deficient Tumors**

New Data

- Sharing preclinical and translational data on ATR inhibition in ATM-deficient cancers
- Presenting clinical results from Phase I showing strong efficacy, including a 50% objective response rate
- Highlighting the differentiated strategy of combining ATR inhibition with low-dose chemotherapy to overcome past limitations of monotherapy
- Showcasing patient vignettes and narratives to illustrate real-world impact and translational success

**Graeme Smith**
Chief Scientific Officer
**Artios Pharma**

**Ian Smith**
Chief Medical Officer
**Artios Pharma**

Combination Strategy

12:15 **Networking Lunch**

## Uncovering Emerging DDR Targets Beyond PARP to Expand Synthetic Lethality Approaches & Improve Patient Outcomes

1:30 **Advancing PARG Inhibition: From Preclinical Rationale to Early Clinical Development**

New Data

- See how FoRx Therapeutics are progressing PARG inhibition with FORX-428 to differentiate from other DDR targets
- Positioning FORX-428 as a best-in-class candidate for PARG inhibition in cancer treatment
- Updating on the translational research activities and biomarker identification for patient selection in the ongoing phase I clinical study of FORX-428

**Irena Konstantinova**
Head of Biology
**FoRx Therapeutics**

2:00 **Introducing DHX9 & ATX-559 as a Novel DDR Program to Broaden Therapeutic Opportunities in Early-Phase Trials**

- See how Accent Therapeutics are pioneering DHX9-targeted therapy with their lead compound ATX-559
- Outlining the Phase 1 trial dose-escalation design and key study objectives
- Sharing translational insights from preclinical data, including biomarker strategy and combination potential to guide future development

**Jennifer Castro**
Director of Translational & Discovery Biology
**Accent Therapeutics**

2:30 **Exploring WRN Inhibition in MSI Tumors to Expand Synthetic Lethality Strategies Beyond PARP**

- See how the MD Anderson Cancer Center are advancing first-in-human trial data for WRN inhibitors in MSI solid tumors
- Interpreting translational relevance and biomarker integration
- Positioning WRN as a synthetic lethality target beyond PARP

**Tim Yap**
Vice President & Head of Clinical Development & Therapeutics Discovery Medical, Institute For Applied Cancer Science
**MD Anderson Cancer Center**

3:00 **Afternoon Break & Networking**

## Exploring Clinical Design, AI Innovation, and Scientific Rethinking to Shape the Future of DDR Therapeutics

3:30 **Innovating Clinical Trial Designs to Accelerate DDR–Radiotherapy Combination Development**

- Pioneering a novel approach to dose escalation in radiotherapy–DDR inhibitor trials that reduce delays by testing multiple agents in parallel
- Applying adaptive statistical methods enabling faster determination of safe, effective doses
- Extending early data from lung cancer studies to brain tumors and other hard-to-treat cancers

**Anthony Chalmers**
Professor & Clinical Oncology Chair
**University of Glasgow**

# Conference Day Two

Thursday, January 29, 2026



4:00 **Harnessing AI-Driven Drug Discovery to Accelerate Next-Generation DDR Therapeutics**

New Data

- See Rakovina Therapeutic's journey of pivoting a DDR-focused biotech to a fully AI-driven discovery model
- Illustrating case studies of AI-designed DDR programs advancing through preclinical lead selection
- Evaluating predictive accuracy, translational potential, and long-term impact of AI on drug development

**Mads Daugaard**
Co-founder, President & Chief Scientific Officer
**Rakovina Therapeutics**

4:30 **Roundtable Discussion: Challenging Dogma & Re-examining DDR Science to Truly Improve Patient Outcomes**

- Reflecting on why preclinical mechanisms often fail in the clinic and exploring new ways to rethink PARP inhibitor mechanisms and dosing strategies
- Debating whether current success metrics in DDR drug development align with meaningful patient outcomes and explore shifting the focus to long-term benefit and resistance avoidance
- Sharing cross-disciplinary perspectives on how biomarkers, experimental tools, and trial design innovations can advance precision medicine

**Shridar Ganesan, MD**
Director, Center for Molecular Oncology
**Perlmutter Cancer**
**NYU Langone Health**

5:00 **Chair's Closing Remarks**

**"This summit serves as a premier platform to explore novel innovations and cutting-edge preclinical and clinical science in DDR mechanisms. Attending the summit provides invaluable insights into the latest advancements in the field, allowing participants to stay abreast of emerging trends and research."**

**Jatinder (Jyoti) Mukker**, Senior Director & Portfolio Section Head, Quantitative Pharmacology, **EMD Serono**

# Showcase Your Services

## Maximize New Connections in Preclinical & Clinical DDR Inhibitor Drug Development

As the only industry-led summit dedicated exclusively to development DDR inhibitors, this meeting brings together leading biopharma, biotech, and academic experts advancing next-generation targets, smarter combinations, and biomarker-driven strategies. With growing momentum around novel mechanisms like ATR, WEE1, and replication stress, and increasing demand for translational tools and clinical support, this is the ideal moment to position your solutions at the forefront of innovation.

Whether you're enabling precision diagnostics, supporting trial execution, or accelerating discovery, this summit offers direct access to decision-makers shaping the future of DDR therapeutics.

## Why Partner?

**Stand out in a highly specialized, industry-leading forum**

Position your company as a strategic partner to a focused audience of 90+ DDR drug developers, biotechs, and academics who are actively searching for new technologies, partners, and solutions in targeted oncology

**Showcase your expertise to an audience seeking innovation**

Demonstrate your expertise and unique offerings to industry leaders looking for innovative partners in diagnostics, CRO services, and integrated drug discovery, and position your brand as a key player in the DDR field

**Connect directly with your target market and shape future collaborations**

Network directly with decision-makers who are seeking new collaborations, commercial partnerships, and the latest advances to accelerate DDR-targeted drug development

## Our Audience Has Highlighted Interest In:

**Advanced diagnostics & biomarker solutions** to help identify predictive biomarkers and enable precision patient selection

**Contract research organizations (CROs)** to effectively support translational and clinical development

**Integrated drug discovery platforms** to accelerate DDR inhibitor discovery and optimization

## Company Types Attending:




## Audience breakdown:

- C-Level/VP: **26%**
- Director: **24%**
- Scientist/Academic Researcher: **35%**
- Other: **15%**

*Statistics Taken from the 8th DDR Inhibitors Summit

# Get Involved

**Anika Johal**
**Partnerships Director**
Email: sponsor@hansonwade.com
Tel: +1 617 455 4188

# Ready to Register?

Please select appropriate price when booking.
Bookings are subject to approval.

## 3 Easy Ways To Book

www.ddr-inhibitors-summit.com/take-part/register

info@hansonwade.com

+1 617 455 4188

1. **DISCOVER** how leading drug developers are advancing the DDR landscape beyond PARP inhibition by validating novel targets such as ATR, CHK1/2, DNA-PK, WEE1, and replication stress pathways.
2. **BUILD** your understanding of predictive biomarkers, functional assays, optimized dosing, and smart DDR combinations with radiotherapy, chemotherapy, ADCs, and radiopharmaceuticals to enhance efficacy and overcome resistance.
3. **ENGAGE** with a global community of DDR experts across pharma, biotech, and academia to forge collaborations, share translational insights, and explore disruptive approaches including AI-driven drug design and novel biomarker strategies.

| Drug Developers* | Register & Pay By Friday, October 17 To Save | On the Door |
|---|---|---|
| Pre-Conference Biomarker Focus Day + Conference | $3,297 **(Save $900)** | $4,197 |
| Conference Day Only | $2,499 **(Save $500)** | $2,999 |

| Academic & Research Institutes** | Register & Pay By Friday, October 17 To Save | On the Door |
|---|---|---|
| Pre-Conference Biomarker Focus Day + Conference | $2,697 **(Save $900)** | $3,597 |
| Conference Day Only | $2,099 **(Save $500)** | $2,599 |

| Service Providers*** | Register & Pay By Friday, October 17 To Save | On the Door |
|---|---|---|
| Pre-Conference Biomarker Focus Day + Conference | $4,197 **(Save $900)** | $5,097 |
| Conference Day Only | $3,199 **(Save $500)** | $3,699 |

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

*** If you are a solution or service provider, have you considered sponsoring this event? Sponsorship includes multiple passes at a discounted rate. Email sponsor@hansonwade.com to learn more

## Team Discounts

- 10% discount - 2 passes
- 15% discount - 3 passes
- 20% discount - 4+ passes

Please note that discounts are only valid when two or more delegates from one company book and pay at the same time. Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate. Contact: register@hansonwade.com

## Venue

**Revere Hotel Boston Common**
200 Stuart Street, Boston, Massachusetts 02116

**www.reverehotel.com**